2020 Exhibitors Search
GENEmedicine
Booth no.
C21
| Country | Korea, South |
|---|---|
| Address | |
| Tel (Rep.) | 02-6214-3237 |
| undecided | |
| Website | http://www.gene-medicine.com |
Company Introduction
GeneMedicine is a company specializing in the development of oncolytic virus through state-of-the-art genetic engineering. Our company has developed and patented a nano material-based platform technology that allows efficient and tumor-targeted delivery of oncolytic virus by systemic administration. GM101 has completed phase 1 clinical trial and further clinical development is underway, aiming for drug approval by 2024. GM102, 103 will begin their respective clinical trial in 2021 and 2022.
Promotional video
Exhibit Item
Oncolytic adenovirus GM101 (Solid tumor; Preparing
Exhibit Item Images
-
Exhibit Name : Oncolytic adenovirus GM101, GM102, GM103Commercialized oncolytic viruses and those under clinical development have several inherent limitations that limit their overall therapeutic efficacy.GeneMedicine's patented oncolytic viruses under preclinical and clinical development can address the limitations of existing oncolytic viruses, targeted cancer therapeutics,cancer immunotherapeutics.
Exhibit Description
Commercialized oncolytic viruses and those under clinical development have several inherent limitations that limit their overall therapeutic efficacy.GeneMedicine's patented oncolytic viruses under preclinical and clinical development can address the limitations of existing oncolytic viruses, targeted cancer therapeutics,cancer immunotherapeutics.
Co-Exhibitor or Partner’s Information
| Company Name | Country |
|---|---|
| undecided | undecided |
KYUNGYON EXHIBITION CORP.